Nrf2:一个关键的调节器在化学或放射治疗耐药性骨髓瘤的骨髓瘤
Xianglin Peng1,2, Jing Feng1,2, Han Yang3,4
1Department of Orthopedics, Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Genes & diseases
|April 17, 2025
概括
核因子E2相关的因子2 (Nrf2) 过度活化驱动骨髓瘤 (OS) 对化疗和辐射的抗性. 向Nrf2可能会改善这种具有挑战性的骨癌的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 骨髓瘤 (OS) 是儿童和青少年常见的骨癌,其生存改善有限.
- 在OS的治疗失败通常是由于耐化疗和放射治疗以及转移的原因.
- 核因子E2相关因子2 (Nrf2) 是细胞平衡的一个关键因素,但它在癌症中的作用是复杂的.
研究的目的:
- 审查骨髓瘤中化学或放射治疗耐药性的机制.
- 阐明核因子E2相关因子2 (Nrf2) 在促进OS化学或放射治疗耐药性的作用.
- 探索对骨髓瘤的Nrf2向治疗策略.
主要方法:
- 关于骨髓瘤治疗耐药性的研究的文献综述.
- 对癌细胞中Nrf2信号通路的分析.
- 检查Nrf2在OS进展中的非抗氧化功能.
主要成果:
- 在癌细胞中过度激活的Nrf2通过限制活性氧物种,增强DNA修复和增加药物流量来促进抵抗力.
- Nrf2还驱动OS的扩散,转移和代谢失调.
- Nrf2在信号网络中起着重要的作用,有助于治疗耐药性.
结论:
- Nrf2是骨髓瘤中化学放射治疗耐药性的关键调解剂.
- 向Nrf2是一个潜在的治疗策略,可以克服OS的治疗失败.
- 为了开发有效的治疗方法,对Nrf2多方面的作用进行进一步的研究是必不可少的.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Transducer Mechanism: Nuclear Receptors
1.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.2K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K


